Table 1.

The detailed characteristics of the final nine included studies

First author	Year	Trial design	Treatment	Typle	PD-L1positive(%)	Line of therapy ≥ 2(%)	Patients enrolled	Dose	Median age	Median OS (months, 95% CI)	Median PFS (months, 95% CI)	1-Year OS(%)	1-Year PFS(%)	ORR (%)	DCR (%)	Any AEs	Grade ≥ 3 AEs	NOS score
C. Hsu	2017	Single-arm phaseI	Pembrolizumab	PD-1	NA	81.5	27	10mg/kg q2w	52	16.5 (10.1–NR)	6.5(3.6–13.4)	63	33.4	25.9	77.8	74.1	29.6	7
Brigette B.Y. Ma	2018	Single-arm phaseII	Nivolumab	PD-1	40	100	44	3mg/kg q2w	57	17.1(10.9-NR)	2.8(1.8–7.4)	59	19.3	20.5	54.5	NA	22.2	8
Wenfeng Fang	2018	Single-arm phaseI	Camrelizumab	PD-1	NA	76	91	1 mg/kg, 3 mg/kg, and 10 mg/kg, and a bridging dose of 200 mg per dose once q2w	45	NA	5.6(3.3–7.9)	NA	NA	34	59	97	17	8
Yunpeng Yang	2021	Single-arm phaseII	Camrelizumab	PD-1	73.1	100	156	200mg q2w	48	17.4(15.2–21.9)	3.7(2.0-4.1)	NA	NA	28.2	54.5	99.4	33.3	8
Feng-Hua Wang	2021	Single-arm phaseII	Toripalimab	PD-1	25.3	48.4	190	3mg/kg q2w	46	17.4(11.7–22.9)	1.9(1.8–3.5)	NA	NA	20.5	40	74.2	14.2	8
Delord, J. P.	2017	Single-arm phase I/II	Nivolumab	PD-1	NA	NA	24	240mg q2w	NA	NR	2.4(1.5-NR)	NA	NA	20.8	45.8	NA	NA	5
Xiaozhong Chen	2020	Single-arm phase II	Penpulimab	PD-1	38.7	100	111	200mg q2w	NA	NA	NA	NA	NA	27	49.5	79.2	14.6	7
Caroline Even	2021	Randomized Phase II	Spartalizumab vs.Chemotherapy	PD-1	95.1	80.5	82	400mg q4w	51	25.2(13.1-NR)	1.9(1.8–3.6)	NA	27.1	17.1	42.7	72	17.1	9
A.T. Chan	2021	Randomized Phase III	Pembrolizumab vs.Chemotherapy	PD-1	74.4	NA	117	200mg q3w	NA	17.2(11.7–22.9)	4.1(2.1–5.6)	40.2	NA	21.4	50.4	61.2	10.3	7

PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; DCR: Disease control rate; NA: Not available; NR: Not reach; AEs: Adverse events